Services on Demand
- Cited by SciELO
- Access statistics
- Cited by Google
- Similars in SciELO
- Similars in Google
Revista Brasileira de Anestesiologia
Print version ISSN 0034-7094
DUMAN, Erdem Nail; SAYLAN, Sedat and CEKIC, Bahanur. Perioperative management of a pediatric patient with glanzmann's thrombasthenia during adenoidectomy. Rev. Bras. Anestesiol. [online]. 2012, vol.62, n.4, pp. 551-553. ISSN 0034-7094. http://dx.doi.org/10.1590/S0034-70942012000400009.
BACKGROUND AND OBJECTIVE: Glanzmann's thrombasthenia (GT) is an autosomal recessively inherited platelet disorder. There is not any specific treatment. Platelet transfusion is currently the standard treatment when bleeding does not respond to local measures and/or antifibrinolytic treatment, although it may result in alloimmunization. Recombinant activated factor VII (rFVIIa) might be used to avoid recurrent platelet transfusion. CASE REPORT: We present early treatment with low-dose rFVIIa additional to platelet transfusion in a 5-year-old pediatric case with diagnosis of GT who developed prolonged bleeding under an elective adenoidectomy surgery. A total dose of 1,200 µg (60 µg.kg-1) rFVIIa could successfully stop bleeding, what can be accepted as low dose usage. CONCLUSIONS: Such case reports may encourage the use of early treatment with low doses of rFVIIa in severe bleeds that did not stop despite of platelet transfusion, as well as in preventing bleeding in surgical procedures in patients with GT. Actually, additional studies are needed to define the minimal effective dose and attempts to determine the lowest effective dose may be encouraged by the result of this case, considering financial restrictions in the health care system.
Keywords : Anesthesia, General; Adenoidectomy; Factor VIIa [recombinant VIIa]; Thrombasthenia.